[Experiment to potentiate the effect of cyclophosphamide combined with tempidon and caffeine in leukemia L1210 and Lewis hepatic carcinoma].
The authors carried out experiments on mice DBA/2 and BDF1 with leucosis L1210 and lung carcinoma of Lewis and found that psycotropic preparations tempidone and caffeine did not manifest antitumorous effect and toxicity after the used doses and scheme of treatment. Tempidone enhanced antitumorous action of small and mean doses of cyclophosphamide in mice with leucosis L1210. In the triple combination (tempidone, caffeine and cycl phosamide) the caffeine enhanced this action of tempidone without raising toxicity in mice with leucosis L1210, but not in mice with lung carcinoma of Lewis.
D000818:Animals; D002110:Caffeine / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010880:Piperidines / Q000627:therapeutic use*; D010881:Piperidones / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D014105:Tosyl Compounds / Q000627:therapeutic use; D014216:Triacetoneamine-N-Oxyl / Q000031:analogs & derivatives
D010880:Piperidines; D010881:Piperidones; D011619:Psychotropic Drugs; D014105:Tosyl Compounds; D014216:Triacetoneamine-N-Oxyl; C002273:tempidon; D002110:Caffeine; D003520:Cyclophosphamide
Opit za usivane efekta na tsiklofosfamida, kombiniran s tempidon i kofein pri levkozata L1210 i belodrobniia kartsinom na Liuis.